Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Trial Profile

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Congenital heart defects; Pulmonary hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jan 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 03 Dec 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top